We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




HTS Method Based on 3D Tumor Organoid Cultures

By LabMedica International staff writers
Posted on 30 Apr 2018
A drug development team has described a high-throughput screening (HTS)-compatible method – based on three-dimensional (3D) tumor organoids – for evaluating multiple chemical compounds for potential chemotherapeutic drug candidates.

Traditional high-throughput drug screening in cancer research routinely relies on two-dimensional cell models, which inadequately recapitulate the physiologic context of cancer. More...
Three-dimensional cell models are thought to better mimic the complexity of in vivo tumors. Numerous methods to culture three-dimensional organoids have been described, but most are nonhomogeneous and expensive, and hence impractical for high-throughput screening (HTS) purposes.

Investigators at the Scripps Research Institute (Jupiter, FL, USA) sought to develop an improved screening method based on three-dimensional organoids. To this end, the described in the April 19, 2018, online edition of the journal SLAS Discovery an HTS-compatible method that enabled the consistent production of organoids in standard flat-bottom 384- and 1536-well plates by combining the use of a cell-repellent surface with a bio-printing technology incorporating magnetic force.

This novel method combined specialized high-density microtiter plates formulated with an ultra-low attachment surface along with gold nanoparticles (nanoshuttles), which were used to label cancer cells in vitro. Once labeled, a magnet assembled the cells into a three-dimensional spheroid or organoid structure. This three-dimensional structure was retained, and chemical compounds were added to assess their therapeutic efficacy.

The investigators validated this process by evaluating the effects of well-characterized anticancer agents against four patient-derived pancreatic cancer KRAS mutant-associated primary cells, including cancer-associated fibroblasts. The technology was tested for its compatibility with HTS automation by completing a cytotoxicity pilot screen of around 3300 approved drugs.

Data obtained during the study indicated that the technique could be readily applied to support large-scale drug screening relying on clinically relevant, three-dimensional tumor models directly harvested from patients, an important milestone toward personalized medicine.

Related Links:
Scripps Research Institute


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: iStock

AMP 2026 Underscores Molecular Testing’s Role in Precision Medicine for Women’s Health

Advances in molecular diagnostics are creating new opportunities to improve the detection of sexually transmitted infections, identify antibiotic resistance, and assess cancer recurrence risk in women.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.